I. Ilgisonis

发表

[The Use of Selective Inhibitor of If-Channels Ivabradine in Patients with Ischemic Heart Disease, Heart Failure with High Heart Rate].

E. A. Privalova, Y. Belenkov, I. Ilgisonis, 2019, Kardiologiia.

Angiotensin-Converting Enzyme Inhibitor Therapy Effects in Patients With Heart Failure With Preserved and Mid-Range Ejection Fraction

Y. Belenkov, L. Popova, M. Kozhevnikova, 2021, Cardiology research.

[The Role of Endothelial Dysfunction in the Development of Cardiotoxic Action of Cytostatics in Patients with Lymphoproliferative Diseases].

V. I. Ershov, Y. Belenkov, I. Ilgisonis, 2019, Kardiologiia.

Vascular Remodeling Markers in Patients with Essential Arterial Hypertension Depending on Presence of Type 2 Diabetes Mellitus

E. A. Privalova, G. Shakaryants, A. Lishuta, 2019, Rational Pharmacotherapy in Cardiology.

Case Report: AL Amyloidosis Severe Restrictive Cardiomyopathy Associated With Multiple Myeloma—Diagnostic Difficulties

I. Ilgisonis, I. Sokolova, E. V. Privalova, 2022, Frontiers in Cardiovascular Medicine.

[Hypertrophic Cardiomyopathy and Ischemic Heart Disease. Variants of Combination Pathology].

V. Kaplunova, M. Kozhevnikova, G. Shakaryants, 2017, Kardiologiia.

Relationship Between Markers of the Acute Phase of Inflammation, Parameters of Blood Lipid Composition and Intracardiac Hemodynamics During Chemotherapy in Patients With Multiple Myeloma.

E. Privalova, Y. Belenkov, I. Ilgisonis, 2022, Kardiologiia.

Left Atrium Involvement in Lymphoma Patients: Single Center Observational Study

E. Privalova, Y. Belenkov, I. Ilgisonis, 2022, Rational Pharmacotherapy in Cardiology.

The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19

Y. Belenkov, I. Ilgisonis, I. Menshikova, 2020, Sechenov Medical Journal.

Hypertrophiccardiomyopathy: forms and variants of the course, approaches to pharmacotherapy.

V. Kaplunova, M. Kozhevnikova, G. Shakaryants, 2018 .

Positive effect of if-channel’s blocker ivabradine therapy in a patient with ischemic chronic heart failure with preserved left ventricle ejection fraction and hereditary thrombophilia (clinical case)

I. Belenkov, I. Ilgisonis, A. Zhito, 2019, CardioSomatics.

Metabolic Syndrome: Development of the Issue, Main Diagnostic Criteria

V. Kaplunova, M. Kozhevnikova, G. Shakaryants, 2018, Rational Pharmacotherapy in Cardiology.

Correlation between the level of C-reactive protein and the parameters of the functional status of the left atrium in patients with lymphoproliferative diseases against the background of chemotherapy

T. Kulagina, E. Privalova, Y. Belenkov, 2023, Clinical Medicine (Russian Journal).

Prognostic value of vascular remodeling parameters in the development of adverse cardiovascular events in patients with gastric cancer

Y. Belenkov, I. Ilgisonis, Y. Kirichenko, 2022, Russian Journal of Cardiology.

Cardiovascular toxicity of antitumor therapy: effect on myocardial and vascular remodeling

E. Privalova, Y. Belenkov, I. Ilgisonis, 2021, Cardiovascular Therapy and Prevention.

[Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers].

E. Privalova, Y. Belenkov, I. Ilgisonis, 2019, Kardiologiia.

Possible pathway for heart failure with preserved ejection fraction prevention and treatment: the angiotensin-converting enzyme inhibitor effect on endothelial function in comorbid patients.

M. Kozhevnikova, E. Privalova, Y. Belenkov, 2022, Kardiologiia.

Changes of myocardial dysfunction and injury biomarkers over chemotherapy for multiple myeloma: difficulties in laboratory data interpretation

Y. Belenkov, I. Ilgisonis, D. A. Budanova, 2023, Rational Pharmacotherapy in Cardiology.